October 16, 2017 06:50 AM EDT

Racing against Alnylam, Ionis posts positive PhIII ATTR efficacy numbers, but questions linger

One of the big rivalries in biotech right now is the race between Ionis $IONS and Alnylam $ALNY to field a new RNA therapy for …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rac­ing against Al­ny­lam, Io­n­is posts pos­i­tive PhI­II AT­TR ef­fi­ca­cy num­bers, but ques­tions linger